The veterinary drug business of U.S. pharmaceutical giant Pfizer is on the block for a possible sale, spinoff or some other form of full or partial split from its parent. New York-based Pfizer announced July 7 it’s “exploring strategic alternatives” for its Pfizer Animal Health wing as well as its Pfizer Nutrition business, which deals in baby formula and other infant and pediatric products. The company said it expects to complete any transactions in anywhere from 12 to 24 months.
Pfizer Sheds Animal Health Biz
Reading Time: < 1 minute
Related Coverage
explore
Stories from our other publications
-
cattleman’s corner
Calf hormone implants can give environmental, financial wins
-
markets
Key supply and demand factors in the U.S. beef market
-
livestock
Grouping cattle from various sellers to appeal to buyers
-
livestock
Norway’s livestock genetics drive efficiency, sustainability in swine and dairy production
ADVERTISEMENT